Glaukos Co. (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Glaukos Co. (NYSE:GKOS) have been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $147.75.

A number of brokerages have recently commented on GKOS. Piper Sandler set a $140.00 price target on Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus increased their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. UBS Group began coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Stephens raised shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd.

Glaukos Trading Up 0.1 %

Shares of Glaukos stock opened at $156.60 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 12-month low of $83.90 and a 12-month high of $161.13. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of -51.85 and a beta of 1.04. The firm’s 50-day moving average price is $145.94 and its two-hundred day moving average price is $133.49.

Glaukos (NYSE:GKOS) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter last year, the business posted ($0.50) EPS. The company’s revenue was up 23.9% compared to the same quarter last year. On average, analysts forecast that Glaukos will post -1.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,603 shares of company stock worth $2,605,678 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently modified their holdings of GKOS. HighTower Advisors LLC boosted its holdings in shares of Glaukos by 3.3% in the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 103 shares during the last quarter. Values First Advisors Inc. bought a new stake in Glaukos in the third quarter worth about $25,000. New York State Teachers Retirement System boosted its stake in Glaukos by 0.4% in the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after acquiring an additional 200 shares during the last quarter. KBC Group NV grew its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares during the period. Finally, Inspire Investing LLC increased its stake in shares of Glaukos by 6.9% during the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after purchasing an additional 206 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.